GlassScriptPhysician profile
Alexander J Kabiri
NPI 1184725152
$268,466.06
in general payments reported to CMS, 2019-2025
23 companies · $41K in 2025
The $41K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107K · 2020: $51K · 2021: $29K · 2022: $7,646 · 2023: $9,538 · 2024: $23K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $55K · Consulting Fee: $8,875 · Food and Beverage: $5,160 · Travel and Lodging: $4,738 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $55,000.00 |
| Consulting Fee | $8,875.00 |
| Food and Beverage | $5,159.64 |
| Travel and Lodging | $4,737.50 |
| Education | $107.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $72,346.11 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55,911.12 | 2019-2021 | |
| Shire North American Group INC | $31,463.11 | 2019 | |
| Aerie Pharmaceuticals, INC. | $30,416.18 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $28,347.99 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $21,074.76 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $10,028.58 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $7,770.93 | 2019-2023 | |
| Allergan, INC. | $6,846.00 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $2,148.00 | 2020 | |
| Alcon Vision LLC | $404.53 | 2019-2025 | Tryptyr, Rocklatan |
| Harrow Eye, LLC | $356.35 | 2024-2025 | Vevye |
| Dompe US, INC. | $345.52 | 2019-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $241.32 | 2021-2025 | Acthar |
| Quidel Corporation | $196.36 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $148.15 | 2024 | |
| Oyster Point Pharma, INC. | $134.87 | 2022-2025 | Ryzumvi, Tyrvaya |
| Sight Sciences, INC. | $125.53 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $79.99 | 2025 | Xdemvy |
| Abbvie INC. | $46.99 | 2022-2025 | |
| Coopervision INC. | $18.88 | 2019 | |
| Horizon Therapeutics Plc | $14.79 | 2023 | Tepezza |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Kabiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.